Massimo Carlo Mauri

Summary

Affiliation: Ospedale Maggiore
Country: Italy

Publications

  1. pmc Symptom dimensions as predictors of clinical outcome, duration of hospitalization, and aggressive behaviours in acutely hospitalized patients with psychotic exacerbation
    Alessandro Colasanti
    Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Via F Sforza 35, 20122 Milan, Italy
    Clin Pract Epidemiol Ment Health 6:72-8. 2010
  2. doi request reprint Suicide attempts in schizophrenic patients: clinical variables
    M C Mauri
    Department of Neuroscience and Mental Health, University of Milan, IRCCS Foundation Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy Electronic address
    Asian J Psychiatr 6:421-7. 2013
  3. pmc Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia
    Michela Nose
    Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Italy
    Trials 10:31. 2009
  4. ncbi request reprint Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response
    Massimo C Mauri
    Department of Internal Medicine, Clinical Psychiatry, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Clin Pharmacokinet 46:359-88. 2007
  5. ncbi request reprint Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels
    M C Mauri
    Clinical Neuropsychopharmacology Unit, Department of Internal Medicine, Clinical Psychiatry, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Via F Sforza 35, Milano, Italy
    Pharmacopsychiatry 40:89-92. 2007
  6. ncbi request reprint Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs
    Massimo C Mauri
    Clinical Psychiatry, University of Milan, Clinical Neuropsychopharmacology Unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via F Sforza 35, 20122 Milano, Italy
    Schizophr Res 99:7-12. 2008
  7. ncbi request reprint Aggression and psychopharmacological treatments in major psychosis and personality disorders during hospitalisation
    M C Mauri
    Clinical Psychiatry, IRCCS Foundation Cà Granda, Ospedale Maggiore Policlinico, Clinical Neuropsychopharmacology Unit, Via F Sforza 35, 20122 Milano, Italy
    Prog Neuropsychopharmacol Biol Psychiatry 35:1631-5. 2011
  8. ncbi request reprint Hallucinatory disorder: preliminary data for a clinical diagnostic proposal
    Massimo C Mauri
    University of Milan Medical School, IRCCS Ospedale Maggiore di Milano, Milano, Italy
    Cogn Neuropsychiatry 11:480-92. 2006
  9. ncbi request reprint A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia
    Massimo Carlo Mauri
    Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Clin Neuropharmacol 29:126-31. 2006
  10. ncbi request reprint Hallucinatory disorder, an original clinical picture? Clinical and imaging data
    Massimo C Mauri
    Clinical Psychiatry, Clinical Neuropsycopharmacology Unit, Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
    Prog Neuropsychopharmacol Biol Psychiatry 32:523-30. 2008

Collaborators

  • Alfredo Carlo Altamura
  • Alessandra Fiorentini
  • Massimiliano Buoli
  • Isabel Valli
  • Lucia Sara Volonteri
  • Wolfgang Maier
  • Rossella Medori
  • Paolo Girardi
  • Giuseppe Maina
  • Alessandro Rossi
  • Giulio Perugi
  • Paolo Brambilla
  • Carlo A Altamura
  • Silvio R Bareggi
  • M Percudani
  • Pasquale De Fazio
  • Alessandro Colasanti
  • Michela Nose
  • A Colasanti
  • G M Ruggiero
  • Giulia Ida Perini
  • Donatella Moliterno
  • Silvia Paletta
  • Alessandra Mazzocchi
  • Palmiero Monteleone
  • Paola Colombo
  • Annamarie Tasser
  • Raffaella Bivi
  • Antonio Sarnicola
  • Tiziana Sciarma
  • Paola Artioli
  • Farida Ferrato
  • Antonio Ferro
  • Lara Malvini
  • Rossana Travaglini
  • Giuseppe Rossi
  • Raffella Rizzo
  • Giuseppe Saraò
  • Stefania Roma
  • Ennio Piantato
  • Alfredo Bisogno
  • Andrea Cipriani
  • Francesco Risso
  • Francesco Pontarollo
  • Marcello Casale
  • Luigi Grassi
  • Francesco Barale
  • Natalia Grazian
  • Liliana Cascone
  • Antonio Veronese
  • Alessia Cicolini
  • Rodolfo Tomasi
  • Ermanna Lazzarin
  • Roger Pycha
  • Walter Di Munzio
  • Gino Targa
  • Giuseppe Migliorini
  • Stylianos Nicholau
  • Anna Maria Pacilli
  • Marco Mollica
  • Simona Ziero
  • Carlo Piazza
  • Gerardo Bertolazzi
  • Antonio Mautone
  • Alessandra Marsilio
  • Barbara Dal Santo
  • Michele De Francesco
  • Francesca Malchiodi
  • Maria Frova
  • Vincenzo Fricchione Parise
  • Francesco Gardellin
  • Francesca Sartore
  • Giuseppe Ducci
  • Giovanni Rossi
  • Alberto Siracusano
  • Silvio Scarone
  • Matteo Rossattini
  • Claudio Santilli
  • Flavio Nosè
  • Nicoletta Fragomeno
  • Marianna Boso
  • Arcadio Erlicher
  • Giancarlo Giupponi
  • Marco Menchetti
  • Stefania Strizzolo
  • Gualtiero Guerrini
  • Eleonora Esposito
  • Nicola Garzotto
  • Bruno Biancosino
  • Domenico Berardi

Detail Information

Publications28

  1. pmc Symptom dimensions as predictors of clinical outcome, duration of hospitalization, and aggressive behaviours in acutely hospitalized patients with psychotic exacerbation
    Alessandro Colasanti
    Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Via F Sforza 35, 20122 Milan, Italy
    Clin Pract Epidemiol Ment Health 6:72-8. 2010
    ..These data indicate that during acute hospitalization due to re-exacerbation of psychosis each symptom dimension has a specific impact on distinct measures of outcome...
  2. doi request reprint Suicide attempts in schizophrenic patients: clinical variables
    M C Mauri
    Department of Neuroscience and Mental Health, University of Milan, IRCCS Foundation Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy Electronic address
    Asian J Psychiatr 6:421-7. 2013
    ..In order to be able to predict and prevent suicide in schizophrenic patients, it is necessary to investigate and characterise suicide victims who meet the criteria for psychotic disorders and risk factors...
  3. pmc Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia
    Michela Nose
    Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Italy
    Trials 10:31. 2009
    ....
  4. ncbi request reprint Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response
    Massimo C Mauri
    Department of Internal Medicine, Clinical Psychiatry, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Clin Pharmacokinet 46:359-88. 2007
    ..A therapeutic range of 100-400 ng/mL is proposed from non-systematic clinical experience. There is no direct evidence concerning optimal plasma concentration ranges of ziprasidone, aripiprazole or sertindole...
  5. ncbi request reprint Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels
    M C Mauri
    Clinical Neuropsychopharmacology Unit, Department of Internal Medicine, Clinical Psychiatry, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Via F Sforza 35, Milano, Italy
    Pharmacopsychiatry 40:89-92. 2007
    ..The aim of this study was to evaluate clinical outcomes and the tolerability of ziprasidone in relation to its plasma levels...
  6. ncbi request reprint Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs
    Massimo C Mauri
    Clinical Psychiatry, University of Milan, Clinical Neuropsychopharmacology Unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via F Sforza 35, 20122 Milano, Italy
    Schizophr Res 99:7-12. 2008
    ....
  7. ncbi request reprint Aggression and psychopharmacological treatments in major psychosis and personality disorders during hospitalisation
    M C Mauri
    Clinical Psychiatry, IRCCS Foundation Cà Granda, Ospedale Maggiore Policlinico, Clinical Neuropsychopharmacology Unit, Via F Sforza 35, 20122 Milano, Italy
    Prog Neuropsychopharmacol Biol Psychiatry 35:1631-5. 2011
    ..As no medication is currently approved for the treatment of aggression, pharmacotherapy (often involving drug combinations) is used on a trial-and-error basis with various degrees of response...
  8. ncbi request reprint Hallucinatory disorder: preliminary data for a clinical diagnostic proposal
    Massimo C Mauri
    University of Milan Medical School, IRCCS Ospedale Maggiore di Milano, Milano, Italy
    Cogn Neuropsychiatry 11:480-92. 2006
    ..We compared a group of patients with a clinical picture related to this syndrome to a group of patients with schizophrenia in order to evaluate the possibility of characterising hallucinatory disorder as a diagnostic entity...
  9. ncbi request reprint A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia
    Massimo Carlo Mauri
    Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Clin Neuropharmacol 29:126-31. 2006
    ..05). In conclusion, the higher doses evidence more efficacy on anxiety and suspiciousness, so it seems to be useful to begin therapy with a full dose of the drug to obtain the maximum effect without any significant side effects...
  10. ncbi request reprint Hallucinatory disorder, an original clinical picture? Clinical and imaging data
    Massimo C Mauri
    Clinical Psychiatry, Clinical Neuropsycopharmacology Unit, Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
    Prog Neuropsychopharmacol Biol Psychiatry 32:523-30. 2008
    ....
  11. ncbi request reprint Clinical outcome and olanzapine plasma levels in acute schizophrenia
    M C Mauri
    Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS Ospedale Maggiore, Via F Sforza 35, 20122 Milan, Italy
    Eur Psychiatry 20:55-60. 2005
    ..This open label study was performed to evaluate the relationship between the plasma concentration of olanzapine and the response in acute schizophrenic inpatients...
  12. ncbi request reprint Patterns of clinical use of antipsychotics in hospitalized psychiatric patients
    Massimo C Mauri
    Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, Ospedale Maggiore Policlinico IRCCS, Via Sforza 35, 20122, Milan, Italy
    Prog Neuropsychopharmacol Biol Psychiatry 29:957-63. 2005
    ..The results of this study confirm the trend to use combinations of one typical and one atypical antipsychotic, and higher doses...
  13. ncbi request reprint Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients
    Lucia Sara Volonteri
    Department of Neuroscience, Clinical Psychiatry, Ospedale Fatebenefratelli and Oftalmico, Milan, Italy
    Psychopharmacology (Berl) 210:489-97. 2010
    ..The relationship between RSP and 9-OH-RSP plasma levels, and clinical response or tolerability has not yet been thoroughly assessed...
  14. ncbi request reprint Substance-induced psychoses: a critical review of the literature
    Alessio Fiorentini
    Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, IRCCS Foundation Ospedale Maggiore Policlinico, Milano MI, Italy
    Curr Drug Abuse Rev 4:228-40. 2011
    ..There remains a striking paucity of information on the outcomes, treatments, and best practices of substance-induced psychotic episodes...
  15. doi request reprint Understanding the pharmacokinetics of anxiolytic drugs
    Alfredo Carlo Altamura
    University of Milan, IRCCS Foundation Cà Granda, Ospedale Maggiore Policlinico, Department of Clinical Psychiatry, Via F Sforza 35, 20122 Milan, Italy
    Expert Opin Drug Metab Toxicol 9:423-40. 2013
    ..For this reason, anxiolytics are the most prescribed psychoactive drugs, particularly in the Western world...
  16. doi request reprint Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group
    Pasquale De Fazio
    Clinical Psychiatry, University Magna Graecia of Catanzaro, Catanzaro, Italy
    Clin Drug Investig 30:827-41. 2010
    ..However, careful evaluation of the individual patient and a thorough risk/benefit assessment should be made prior to initiating any treatment plan...
  17. doi request reprint White matter metabolism differentiates schizophrenia and bipolar disorder: a preliminary PET study
    Alfredo Carlo Altamura
    Department of Neurosciences, University of Milan, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
    Psychiatry Res 214:410-4. 2013
    ..This feature may characterize and differentiate the regional brain metabolism of the two illnesses...
  18. ncbi request reprint Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder
    Massimiliano Buoli
    University of Milan, Department of Psychiatry, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
    Expert Opin Drug Metab Toxicol 10:885-92. 2014
    ..Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD)...
  19. ncbi request reprint Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels
    M C Mauri
    Department of Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS Ospedale Maggiore, Via F Sforza 35, 20122 Milan, Italy
    Eur Psychiatry 16:57-63. 2001
    ..RSP seems to be quite an effective drug. It seems, however, difficult to devise appropriate dose schedules and plasma level determination seems to be necessary in some cases...
  20. ncbi request reprint Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg
    Massimo Carlo Mauri
    Clinical Psychiatry, University of Milan, Clinical Neuropsychopharmacology Unit, IRCCS Ospedale Maggiore di Milano, Milano, Italy
    Int J Psychiatry Clin Pract 13:36-47. 2009
    ..57% with lower doses; P<0.0001), although most AEs were mild to moderate in severity. Conclusion. In this study, 25 mg RLAI was the most commonly prescribed dose. RLAI was effective and well tolerated over the full range of doses. ..
  21. ncbi request reprint Psychiatric diagnosis and aggression before acute hospitalisation
    A Colasanti
    Clinical Psychiatry, Guardia II, University of Milan, Clinical Neuropsychopharmacology Unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via F Sforza 35, 20122 Milan, Italy
    Eur Psychiatry 23:441-8. 2008
    ..To examine the predictors of aggressive behaviours occurring before acute hospitalisation...
  22. ncbi request reprint Clozapine metabolism rate as a possible index of drug-induced granulocytopenia
    M C Mauri
    Department of Clinical Psychiatry, University of Milan, I R C C S Ospedale Maggiore di Milano, Italy
    Psychopharmacology (Berl) 137:341-4. 1998
    ..002, r = 0.25). These preliminary data suggest that the NCLZ/CLZ ratio, as an index of CLZ metabolism, might be a possible risk factor associated with CLZ treatment...
  23. ncbi request reprint Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine
    A C Altamura
    Department of Clinical Psychiatry, University of Milan, Italy
    Pharmacopsychiatry 22:246-9. 1989
    ..The HL daily dose (mg/kg), ORD plasma levels and the TOF/ORD plasma level ratio seem to influence significantly the severity of residual extrapyramidal side-effects...
  24. ncbi request reprint Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels
    L S Volonteri
    Department of Clinical Psychiatry, Ospedale Fatebenefratelli and Oftalmico, Milan, Italy
    J Psychopharmacol 24:1193-9. 2010
    ..Our findings suggest that monitoring plasma DLX levels may be helpful in predicting better treatment responses and tolerability. The present data seem to suggest an optimal anxiolytic efficacy of DLX at intermediate plasma levels...
  25. ncbi request reprint A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics
    G M Ruggiero
    Department of Clinical Psychiatry, University of Milan, Italy
    Prog Neuropsychopharmacol Biol Psychiatry 25:1049-59. 2001
    ..4. Patients treated with amisulpride showed a more significant increase (p=0.016) of mean weight. Concerning weight phobia, body image disturbance and amenorrhoea, no significant difference resulted...
  26. ncbi request reprint Alcoholism and depression: a placebo controlled study with viloxazine
    A C Altamura
    Department of Clinical Psychiatry, University of Milan, Italy
    Int J Clin Pharmacol Res 10:293-8. 1990
    ..All patients showed baseline haematochemical evidence of liver dysfunction that did not change significantly during the treatment...